Results 231 to 240 of about 1,666,845 (324)
Global and Regional Temporal Changes in Cross‐Country Inequalities of Site‐Specific Osteoarthritis Burden, 1990 to 2021
Arthritis Care &Research, EarlyView.Objective
This study examined the global and regional temporal changes in cross‐country inequalities of site‐specific osteoarthritis (OA) burden from 1990 to 2021. Methods
Age‐standardized years lived with disability rates (ASYRs) for site‐specific OA across 204 countries and territories were obtained from the Global Burden of Diseases, Injuries, and ...Haowei Chen, Lei Si, David J. Hunter, Lei Zhang, Zhe‐Sheng Chen, Xiaomeng Wang, Vicky Duong, Zhounan Zhou, Peihua Cao, Han Cen, Su'an Tang, Tianyu Chen, Houjun Xue, Zhaohua Zhu, Changhai Ding +14 morewiley +1 more sourceRNA editing for the treatment of alpha-1 antitrypsin deficiency. [PDF]
Nucleic Acids ResMonian P, Shivalila C, Lu G, Bowman K, Briem S, Bylsma M, Byrne M, Cannon M, Chatterjee A, Dallaire M, Desai J, Dufresne J, Faraone A, Favaloro F, Friend S, Ghosh A, Godfrey J, Hernandez N, Huth O, Iwamoto N, Kawamoto T, Lamattina A, Lemaitre M, Lindsey A, Liu F, Looby R, Luu K, McGlynn A, Metterville J, Paik IH, Pan Q, Patil S, Pu T, Purcell-Estabrook E, Ranade A, Rheinhardt J, Rossi J, Shimizu M, Singh K, Standley S, Thomas C, Tripathi S, Yang H, Yordanoff R, Yin Y, Yu H, Narayanan P, Kandasamy P, Giangrande PH, Vargeese C. +49 moreeuropepmc +1 more sourceImprovements in Health‐Related Quality of Life With Treat‐to‐Target Urate‐Lowering Therapy in Gout: A Post Hoc Analysis of a Randomized Multicenter Trial
Arthritis Care &Research, EarlyView.Objective
Although treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL ...Austin Barry, Bryant R. England, Harlan Sayles, Lindsay N. Helget, Maria Androsenko, Hongsheng Wu, Kaleb Michaud, Bridget Kramer, Jeff A. Newcomb, Mary T. Brophy, Anne Davis‐Karim, Ryan Ferguson, Michael H. Pillinger, Tuhina Neogi, Paul M. Palevsky, James R. O'Dell, Ted R. Mikuls +16 morewiley +1 more sourceOutcomes of aortic and mitral valve replacement with Dafodil™ pericardial bioprosthesis over 5-years: Dafodil™-1 trial. [PDF]
Front Cardiovasc MedHiremath CS, Jain A, Garg A, Maslekar A, Gupta N, Sarkar BK, Bhat S, Porwal M, Singh Meharwal Z, Mishra YK, Vaijyanath P, Grover V, Chaudhary SK, Rajput SS, Sethuratnam R, Shastri N, Padmanabhan C, Thakur NT, S J C, Naik D, Gupta VK, Sancheti A. +21 moreeuropepmc +1 more sourceMonocyte LOXHD1 and RHOB Expression Predictive of Progressive Systemic Sclerosis–Associated Interstitial Lung Disease
Arthritis Care &Research, EarlyView.Objective
A leading cause of death among patients with scleroderma (SSc), interstitial lung disease (ILD) remains challenging to prognosticate. The discovery of biomarkers that accurately determine which patients would benefit from close monitoring and aggressive therapy would be an essential clinical tool.Cristina M. Padilla, Robert Lafyatis, Kevin F. Gibson, Christina Morse, Eleanor Valenzi, Xiaoping Chen, Xiaoyun Li, Yanwu Zhao, Yongseok Park, Dana Ascherman, Jonathan Minden, Robyn Domsic, Yingze Zhang, Daniel J. Kass +13 morewiley +1 more sourceEnsembl 2026. [PDF]
Nucleic Acids ResYates AD, Austine-Orimoloye O, Azov AG, Barba M, Barnes I, Barrera-Enriquez VP, Becker A, Bennett R, Berry A, Bhai J, Bhurji SK, Branco Lins PR, Brooks L, Budhanuru Ramaraju S, Campbell LI, Carbajo Martinez M, Carpenter J, Charkhchi M, Cortes LA, Davidson C, Dickson S, Dodiya K, Donaldson S, El Houdaigui B, El Naboulsi T, Fairbrother-Browne A, Falola O, Fatima R, Gonzalez Martinez J, Gurbich T, Hall H, Hardy M, Hollis Z, Hunt T, Kay M, Kaikala V, Lazar A, Lemos D, Lodha D, Mathlouthi N, Merino GA, Merritt R, Mirabueno LP, Mushtaq A, Nakib Hossain S, Pérez-Silva JG, Piližota I, Poppleton D, Prosovetskaia I, Raj S, Salam AIA, Saraf S, Sinha S, Sipos B, Sitnik V, Suner MM, Surapaneni L, Tierney JAS, Urbina-Gómez D, Veidenberg A, Walsh TA, Allen JM, Alvarez-Jarreta J, Cheema J, Batista da Rocha J, De Silva NH, Tricomi FF, Giorgetti S, Ilsley GR, Keatley J, Loveland JE, Mudge JM, Naamati G, Tate J, Willhoft NL, Winterbottom A, Flint BR, Frankish A, Haggerty L, Hunt SE, Clark EL, Dyer SC, Freeberg MA, Martin FJ, Finn RD. +84 moreeuropepmc +1 more sourceHeterogeneity of Rheumatoid Arthritis–Associated Interstitial Lung Disease by Longitudinal Forced Vital Capacity Trajectory and Associations With Disease Outcomes
Arthritis Care &Research, EarlyView.Objective
We aimed to identify unique disease trajectories within rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) based on longitudinal forced vital capacity (FVC) values and their associated clinical outcomes. Methods
We performed a cohort study of RA‐ILD within the Veterans Health Administration from 1999 to 2021.Bryant R. England, Yangyuna Yang, Punyasha Roul, Tate M. Johnson, Scott M. Matson, Grant W. Cannon, Brian C. Sauer, Jeffrey R. Curtis, Joshua F. Baker, Ted R. Mikuls +9 morewiley +1 more source
